ASCO 25: Enhertu Bids for Earlier Use in HER2+ Breast Cancer

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer

Enhertu, used as first option, stalled tumors for more than a year in women with breast cancer, study finds

The findings mean the drug from AstraZeneca and Daiichi Sankyo could set a new standard of care in certain cases.

Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine.

Enhertu potential broadens as new data point to frontline breast cancer role

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that's been standard treatment for more than a decade.